Study Suggests Salt Restriction Only Beneficial In People With Hypertension
–More questions raised about broad efforts to restrict salt; AHA condemns study A large new analysis offers more evidence that broad salt restriction doesn’t benefit most people and may even harm some people. The study did find that salt restriction may be beneficial to the minority of people with high blood pressure who also consume...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - May 22, 2016 Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics Prevention, Epidemiology & Outcomes Uncategorized american heart association guidelines salt sodium Source Type: blogs
Entresto Gets Boost in Updated HF Guidelines
–Valsartan/sacubitril earns Class I recommendation Cardiology groups in the U.S. and Europe have updated their heart failure guidelines to include much-awaited recommendations for Entresto (the combination of valsartan and sacubitril manufactured by Novartis). The new guidelines offer broad support for the new drug. Since its approval last summer Entresto has struggled to gain a foothold...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - May 20, 2016 Category: Cardiology Authors: Larry Husten Tags: Heart Failure People, Places & Events Policy & Ethics Entresto guidelines LCZ Source Type: blogs
Novartis Announces Enormous Clinical Trial Program For Heart Failure Drug
–The company plans to perform 40 clinical trials in 5 years with Entresto. Novartis announced today an enormous clinical trial program with its promising but slow starting heart failure drug Entresto (valsartan/sacubitril). The company said it would perform 40 clinical trials with the drug in the next five years. The Fortifying Heart Failure clinical evidence and...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - May 19, 2016 Category: Cardiology Authors: Larry Husten Tags: Heart Failure People, Places & Events clinical trials Entresto LCZ Source Type: blogs
ASGR1 Gene Tied to Heart Health
–May have stronger impact than PCSK9 variants on disease risk A large new study from Iceland has identified variants in a gene that appear to have powerful cardioprotective effects, perhaps an first early step toward a novel therapy for heart disease prevention and treatment. The gene, ASGR1, was identified by the well known genetic researcher...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - May 18, 2016 Category: Cardiology Authors: Larry Husten Tags: Prevention, Epidemiology & Outcomes ASGR1 cholesterol genetics lipids Source Type: blogs
You Say Potato, I Say Worthless Epidemiology
–Observational study links potatoes to high blood pressure Depending on your position in the dietary wars, potatoes are now either a newly-confirmed nutritional villain or an innocent victim of overzealous and misapplied epidemiology. A new study, published in The BMJ, is the first to establish a direct link between potato consumption and blood pressure. One...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - May 17, 2016 Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics Prevention, Epidemiology & Outcomes nutrition potato Source Type: blogs
Noted Skeptic Calls For More Randomized Nutrition Trials
Defying conventional wisdom Ioannidis says we need more negative trials to clear away all our misconceptions about nutrition Defying conventional wisdom Ioannidis says we need more negative trials to clear away all our misconceptions about nutritionDefying conventional wisdom Ioannidis says we need more negative trials to clear away all our misconceptions about nutritionDefying conventional wisdom...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - May 10, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Ioannidis nutrition randomized trials skepticism Source Type: blogs
Increasing Support For Generic Drugs And Therapeutic Substitution
–But some physicians, perhaps influenced by industry, remain skeptical. Generic drugs and therapeutic substitution (replacing a drug without a generic equivalent with a different but closely related drug in the same general class) are two key ingredients in most recipes to hold down health care costs. Now a package of articles and commentary in JAMA...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - May 9, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics conflict of interest generics statins therapeutic substitution Source Type: blogs
Pioneering Lipoprotein Researcher Richard Havel Dead
–Nobel laureates Brown and Goldstein say when they were starting out Havel taught them 90% of what they knew Richard Havel, a scientist who helped create the entire entire modern field of research in lipoprotein metabolism, died last month. In response to the news scientists in the field have poured extravagant praise on the man...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - May 6, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Prevention, Epidemiology & Outcomes lipoproteins obituary Richard Havel Source Type: blogs
Social Media And Medical Journals: The Streetlight Effect
–Another study tests the wrong approach to social media in medical publishing Here’s the main problem with a new study published in the Journal of the American Heart Association: they measured the wrong thing with the wrong method. In their new paper the researchers randomized new studies appearing in Circulation to receive social promotion...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - May 5, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Facebook promotion social media twitter Source Type: blogs
On Road To Bankruptcy A Stent Company Invested in Marty Leon’s VC Fund
More questions are being raised about the research and financial activities of Palmaz Scientific, the bankrupt medical device company founded by Julio Palmaz, the co-inventor of the stent. In the middle of severe financial troubles that eventually brought the company to bankruptcy Palmaz Scientific found enough money to invest in a venture capital fund. The VC Fund,...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - May 3, 2016 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics Uncategorized bankruptcy grooved stent Martin Leon Palmaz Palmaz Scientific Triventures Source Type: blogs
Experts Foresee Major Role For Generic Crestor
— Finally there’s a challenger to the long reign of Lipitor The FDA approval on Friday of the first generic version of Crestor (rosuvastatin calcium) marks the end of an era and the beginning of a major shift in cardiovascular medicine. Over time, as the price of the drug drops with generic competition, it seems...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - May 2, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Uncategorized atorvastatin Crestor generics Lipitor Rosuvastatin statins Source Type: blogs
New Cardio Drugs Off To Very Slow Start
–Heart failure experts divided over how and when to use Entresto To many long-time observers, the approval last year of two new cholesterol drugs and a heart failure drug appeared to herald a rebirth of the cardiovascular marketplace after a long period of dormancy. But so far in 2016, those new drugs have hardly made...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - April 27, 2016 Category: Cardiology Authors: Larry Husten Tags: Heart Failure People, Places & Events Policy & Ethics drug costs Entresto guidelines LCZ 696 PCSK9 Source Type: blogs
Stent Pioneer’s Company In Bankruptcy And Under Investigation
–Julio Palmaz hasn’t been able to recreate his earlier success A company founded by stent pioneer Julio Palmaz has declared bankruptcy and is being investigated for misconduct, according to the San Antonio Express-News. Palmaz, along with Richard Schatz, was the inventor of the enormously successful Palmaz-Schatz stent marketed by Johnson & Johnson. In March Palmaz...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - April 25, 2016 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics bankruptcy Palmaz Palmaz Scientific SEC stents Source Type: blogs
Companies Plan To Study Diabetes Drug In Heart Failure Population
–New attention paid to the intersection of heart failure and diabetes Boehringer Ingelheim and Eli Lilly announced on Wednesday that they were planning two separate outcomes trials to test the effect of the diabetes drug empagliflozin (Jardiance) in patients with chronic heart failure. The trials herald a remarkable shift in emphasis, since there have been...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - April 21, 2016 Category: Cardiology Authors: Larry Husten Tags: Diabetes Heart Failure People, Places & Events empagliflozin Jardiance Source Type: blogs
No Evidence To Support Screening Young Athletes
–More questions raised about key study suggesting ECG screening can save lives There is no good evidence to support screening young athletes to prevent sudden cardiac arrest, concludes a new analysis published in the BMJ. The analysis also raises new and troubling questions about a key Italian study that has been the main study used...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - April 20, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes open data screening screening athletes Source Type: blogs
